Home
/
PharmaCyte Biotech, Inc.
/
Financials
/
Quarterly
PharmaCyte Biotech, Inc. — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that PharmaCyte Biotech, Inc. filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2026
Jan 31, 2026
$0
Mar 17, 2026
Q2
2026
Oct 31, 2025
$0
Dec 18, 2025
Q1
2026
Jul 31, 2025
$0
Sep 15, 2025
Q3
2026
Jan 31, 2025
$0
Mar 17, 2026
Q2
2026
Oct 31, 2024
$0
Dec 18, 2025
Q1
2026
Jul 31, 2024
$0
Sep 15, 2025
Q3
2025
Jan 31, 2024
$0
Mar 17, 2025
Q2
2025
Oct 31, 2023
$0
Dec 13, 2024
Q1
2025
Jul 31, 2023
$0
Sep 17, 2024
Q3
2024
Jan 31, 2023
$0
Mar 18, 2024
Q2
2024
Oct 31, 2022
$0
Dec 15, 2023
Q1
2024
Jul 31, 2022
$0
Sep 18, 2023
Q3
2023
Jan 31, 2022
$0
Mar 16, 2023
Q2
2022
Oct 31, 2021
$0
Dec 14, 2022
Q1
2023
Jul 31, 2021
$0
Sep 14, 2022
Q3
2022
Jan 31, 2021
$0
Mar 15, 2022
Q2
2022
Oct 31, 2020
$0
Dec 14, 2021
Q1
2022
Jul 31, 2020
$0
Sep 14, 2021
Q3
2021
Jan 31, 2020
$0
Mar 12, 2021
Q2
2021
Oct 31, 2019
$0
Dec 11, 2020
Revenue (Net Sales) — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2016
Jan 31, 2016
$0
Mar 8, 2016
Q2
2016
Oct 31, 2015
$0
Jan 19, 2016
Q1
2016
Jul 31, 2015
$0
Jan 19, 2016
Q3
2016
Jan 31, 2015
$0
Mar 8, 2016
Q2
2016
Oct 31, 2014
$0
Jan 19, 2016
Q1
2016
Jul 31, 2014
$0
Jan 19, 2016
Q3
2015
Jan 31, 2014
$0
Mar 13, 2015
Q2
2015
Oct 31, 2013
$0
Dec 15, 2014
Q1
2015
Jul 31, 2013
$0
Sep 15, 2014
Q3
2014
Jan 31, 2013
$0
Mar 17, 2014
Q2
2014
Oct 31, 2012
$6.3K
Dec 16, 2013
Q1
2014
Jul 31, 2012
$6.6K
Sep 16, 2013
Q3
2013
Jan 31, 2012
$20.3K
Mar 26, 2013
Q2
2013
Oct 31, 2011
$19.8K
Dec 26, 2012
Q1
2013
Jul 31, 2011
$19.8K
Sep 19, 2012
Q3
2012
Jan 31, 2011
$32.0K
Mar 21, 2012
Q2
2012
Oct 31, 2010
$15.9K
Dec 15, 2011
Q1
2012
Jul 31, 2010
$27.0K
Sep 20, 2011
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2026
Jan 31, 2026
$746.9K
Mar 17, 2026
Q3
2026
Oct 31, 2025
($7.42M)
Mar 17, 2026
Q2
2026
Oct 31, 2025
($7.42M)
Dec 18, 2025
Q2
2026
Jul 31, 2025
($8.36M)
Dec 18, 2025
Q3
2026
Jul 31, 2025
($8.36M)
Mar 17, 2026
Q1
2026
Jul 31, 2025
($8.36M)
Sep 15, 2025
Q3
2026
Jan 31, 2025
($3.05M)
Mar 17, 2026
Q2
2026
Oct 31, 2024
($1.47M)
Dec 18, 2025
Q3
2026
Oct 31, 2024
($1.47M)
Mar 17, 2026
Q3
2026
Jul 31, 2024
$23.42M
Mar 17, 2026
Q1
2026
Jul 31, 2024
$23.42M
Sep 15, 2025
Q2
2026
Jul 31, 2024
$23.42M
Dec 18, 2025
Q3
2025
Jan 31, 2024
($619.5K)
Mar 17, 2025
Q2
2025
Oct 31, 2023
$2.79M
Dec 13, 2024
Q3
2025
Oct 31, 2023
$2.79M
Mar 17, 2025
Q3
2025
Jul 31, 2023
($3.18M)
Mar 17, 2025
Q1
2025
Jul 31, 2023
($3.18M)
Sep 17, 2024
Q2
2025
Jul 31, 2023
($3.18M)
Dec 13, 2024
Q3
2024
Jan 31, 2023
($764.1K)
Mar 18, 2024
Q2
2024
Oct 31, 2022
($1.88M)
Dec 15, 2023
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2026
Jan 31, 2026
($2.12M)
Mar 17, 2026
Q2
2026
Oct 31, 2025
($1.38M)
Dec 18, 2025
Q1
2026
Jul 31, 2025
($848.3K)
Sep 15, 2025
Q3
2026
Jan 31, 2025
($960.3K)
Mar 17, 2026
Q2
2026
Oct 31, 2024
($1.11M)
Dec 18, 2025
Q1
2026
Jul 31, 2024
($1.27M)
Sep 15, 2025
Q3
2025
Jan 31, 2024
($1.87M)
Mar 17, 2025
Q2
2025
Oct 31, 2023
($1.41M)
Dec 13, 2024
Q1
2025
Jul 31, 2023
($2.08M)
Sep 17, 2024
Q3
2024
Jan 31, 2023
($1.55M)
Mar 18, 2024
Q2
2024
Oct 31, 2022
($2.32M)
Dec 15, 2023
Q1
2024
Jul 31, 2022
($1.68M)
Sep 18, 2023
Q3
2023
Jan 31, 2022
($856.1K)
Mar 16, 2023
Q2
2022
Oct 31, 2021
($1.00M)
Dec 14, 2022
Q1
2023
Jul 31, 2021
($1.02M)
Sep 14, 2022
Q3
2022
Jan 31, 2021
($756.8K)
Mar 15, 2022
Q2
2022
Oct 31, 2020
($949.5K)
Dec 14, 2021
Q1
2022
Jul 31, 2020
($881.7K)
Sep 14, 2021
Q3
2021
Jan 31, 2020
($875.3K)
Mar 12, 2021
Q2
2021
Oct 31, 2019
($1.07M)
Dec 11, 2020